US pauses new patients on Merck's MS drug, shares dive https://ift.tt/GzKi1cA

Merck shares were down five per cent at 0757 GMT on news of the setback, sliding to the bottom of Germany's blue-chip DAX index. The science and technology group must now place on hold the initiation of new evobrutinib patients and halt studies involving patients who have been taking the drug for less than 70 days.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/TlUfdsG